RxDoctor Payments Data

Paul Gillum, MD

Dermatopathology · Norman, OKNPI 1982602025

Payments from drug & device makers

$810,508in general payments, 2019–2025

Across 130 payments — averaging $6234.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$443K
  • Eli Lilly$158K
  • E.r. Squibb & Sons, L.L.C.$131K
  • Regeneron$55K
  • Astrazeneca UK Limited$17K
  • Janssen Research & Development, LLC$6K
  • plus $14 from 1 others
$763in research payments, 2019–2025

Across 2 payments — averaging $381.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$763

What the payments were for

  • Food & beverage$14100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few dermatopathology providers in Oklahomato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$868,618
Medicare patients
6,593
Services billed
12,033

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Where these figures come from

Is this you, or does something look wrong? →